Jeffrey Wade - Lexicon Pharmaceuticals President
| LXRX Stock | USD 1.74 0.04 2.35% |
President
Mr. Jeffrey L. Wade is Chief Financial Officer, Executive Vice President Corporationrationrate and Administrative Affairs of the company. He was our executive vice president, corporate and administrative affairs and chief financial officer since February 2015 and previously served in a series of finance and legal leadership positions since joining our company in 1999. Mr. Wade was previously a corporate securities and finance attorney for ten years with the law firm of Andrews Kurth L.L.P., where he represented companies in the biotechnology, information technology and energy industries since 2015.
| Age | 53 |
| Tenure | 9 years |
| Phone | 281 863 3000 |
| Web | https://www.lexpharma.com |
Jeffrey Wade Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeffrey Wade against Lexicon Pharmaceuticals stock is an integral part of due diligence when investing in Lexicon Pharmaceuticals. Jeffrey Wade insider activity provides valuable insight into whether Lexicon Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Lexicon Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lexicon Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jeffrey Wade over two months ago Acquisition by Jeffrey Wade of 314320 shares of Lexicon Pharmaceuticals subject to Rule 16b-3 | ||
Jeffrey Wade over six months ago Purchase by Jeffrey Wade of 10000 shares of Lexicon Pharmaceuticals | ||
Jeffrey Wade over a year ago Exercise or conversion by Jeffrey Wade of 30467 shares of Lexicon Pharmaceuticals subject to Rule 16b-3 | ||
Jeffrey Wade over a year ago Acquisition by Jeffrey Wade of 147340 shares of Lexicon Pharmaceuticals subject to Rule 16b-3 |
Lexicon Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5067) % which means that it has lost $0.5067 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.685) %, meaning that it created substantial loss on money invested by shareholders. Lexicon Pharmaceuticals' management efficiency ratios could be used to measure how well Lexicon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Thomas DesRosier | Seres Therapeutics | 63 | |
| Kevin Horgan | Seres Therapeutics | 58 | |
| Erin MD | Terns Pharmaceuticals | 53 | |
| Marcus Chapman | Seres Therapeutics | 47 | |
| Erik MBA | AVROBIO | 52 | |
| Abi VainsteinHaras | BioLineRx | 41 | |
| Kathryn McNaughton | AVROBIO | N/A | |
| Elizabeth Grammer | Ardelyx | 60 | |
| Moshe Phillip | BioLineRx | 62 | |
| Reginal Seeto | Ardelyx | 44 | |
| Michele Trucksis | Seres Therapeutics | 64 | |
| Birgitte Volck | AVROBIO | 56 | |
| Holly MBA | BioLineRx | 62 | |
| David Malek | BioLineRx | 39 | |
| Paul Korner | Ardelyx | 50 | |
| Arnon Aharon | BioLineRx | N/A | |
| Bryan Shaw | Ardelyx | 61 | |
| Ella Sorani | BioLineRx | 56 | |
| Wael Hashad | Seres Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.68 | ||||
| Return On Asset | -0.51 |
Lexicon Pharmaceuticals Leadership Team
Elected by the shareholders, the Lexicon Pharmaceuticals' board of directors comprises two types of representatives: Lexicon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lexicon. The board's role is to monitor Lexicon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lexicon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lexicon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Praveen Tyle, Executive Vice President of Research and Development | ||
| Gary Branch, Vice President - Sales | ||
| Robert Lefkowitz, Independent Director | ||
| Christopher Sobecki, Independent Director | ||
| Raymond Debbane, Independent Chairman of the Board | ||
| Alan Nies, Independent Director | ||
| Pablo Lapuerta, Executive Vice President - Clinical Development, Chief Medical Officer | ||
| Chas Schultz, Executive Advocacy | ||
| Robert MD, Consultant Director | ||
| James Tessmer, Vice President - Finance & Accounting | ||
| Desiree Gendron, Vice Training | ||
| Frank Palantoni, Independent Director | ||
| Judith Swain, Independent Director | ||
| Dixon Terry, Vice Compliance | ||
| Philippe Amouyal, Independent Director | ||
| Carrie Siragusa, Vice Marketing | ||
| Jeffrey Wade, CFO, Executive Vice President - Corporate Development | ||
| Alexander Santini, Chief Commercial Officer | ||
| Kiernan Seth, Vice President - Marketing | ||
| Lisa DeFrancesco, Head Strategy | ||
| Samuel Barker, Independent Director | ||
| Kenneth MD, Senior Assurance | ||
| Lonnel Coats, CEO and President and Director | ||
| Tom Garner, Senior Officer | ||
| Jeffrey JD, President CFO | ||
| Mike Kelly, Investor Officer | ||
| Kristen Alexander, Vice Accounting | ||
| Alan Main, Executive VP of CMC and Supply Operations | ||
| Brian Crum, General VP | ||
| John Northcott, VP of Marketing, Commercial Strategy and Operations | ||
| Wendy McDermott, Vice Resources |
Lexicon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lexicon Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.68 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | (66.58) % | ||||
| Current Valuation | 354.64 M | ||||
| Shares Outstanding | 246.24 M | ||||
| Shares Owned By Insiders | 1.68 % | ||||
| Shares Owned By Institutions | 82.18 % | ||||
| Number Of Shares Shorted | 20.12 M | ||||
| Price To Earning | 21.02 X | ||||
| Price To Book | 5.21 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Lexicon Stock analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexicon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.